Klinikum-Passau
- Address
- Innstraße 76, 94032 Passau, Germany
Klinikum-Passau - Hematologic Malignancies Research Center
Klinikum-Passau is a clinical research center focused on advancing treatment strategies for hematologic malignancies, with particular expertise in acute leukemias and related blood disorders. The center participates in multicenter trials investigating innovative therapeutic approaches for patients with complex blood cancers requiring intensive treatment protocols.
- Acute Myeloid Leukemia (AML) with FLT3 mutations
- Targeted molecular therapies in combination with chemotherapy
- Myelodysplastic syndromes with genetic mutations
The center demonstrates significant commitment to precision medicine in hematology, particularly through participation in comparative effectiveness trials of FLT3 inhibitors such as gilteritinib and midostaurin. Their research emphasizes comprehensive treatment strategies combining targeted therapies with intensive chemotherapy and maintenance protocols, aiming to improve event-free survival and outcomes for patients with genetically defined subtypes of acute myeloid leukemia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum-Passau
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy. | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase III | Not Recruiting | Mar 2019 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 1 | Unknown | 2020-10-23 | 2020-10-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.